Submission of Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025
Awaiting price reaction for this filing.
Aurobindo Pharma has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025 to NSE and BSE, as required under Regulation 24A of SEBI's Listing Regulations. The report, certified by Practicing Company Secretary A. Mohan Rami Reddy, confirms that the company complied with applicable SEBI regulations, secretarial standards, insider trading norms, related party transaction rules, and corporate governance requirements, with no new non-compliances observed. No fresh action was taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries during the year. The only pending matter is an old case under PIT Regulations (relating to promoter share consolidation in FY 2008-09 linked to a Pfizer deal) that was settled with SEBI for Rs 220.2 million in April 2020; a calculation-error dispute is now pending before the Telangana High Court, but it is against the promoters and not the company. Additionally, material subsidiary APL Healthcare Limited appointed G P M & Associates as statutory auditors in place of Reddy A V & Co from July 22, 2024.
This is a routine annual compliance filing with no new adverse actions against the company, so it is largely neutral for the stock. The lingering promoter-level PIT matter is an old, already-settled dispute and is unlikely to materially affect the company's operations or share price.